Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-25
DOI
10.3389/fonc.2021.737767
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review
- (2021) Francesca Matilde Schipilliti et al. Pharmaceuticals
- Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis
- (2021) Junjie Huang et al. Liver Cancer
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
- (2021) Masatoshi Kudo et al. Liver Cancer
- Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma
- (2020) Susumu Maruta et al. Liver Cancer
- Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
- (2020) Jaekyung Cheon et al. Liver Cancer
- Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
- (2020) Dong-Xu Wang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
- (2020) Soojin Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials
- (2020) Sivesh K. Kamarajah et al. HPB
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
- (2019) Tatsuya Yamashita et al. JOURNAL OF GASTROENTEROLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
- (2018) Sheng-Nan Lu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis
- (2017) Yuan-Hung Kuo et al. INVESTIGATIONAL NEW DRUGS
- Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use
- (2017) Yuan-Hung Kuo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology
- (2016) Angela Lamarca et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started